Health Organization (WHO) did not recommend vaccination as part of the solution. Nevertheless, Thailand initiated a nationwide vaccination program in school-age children with an injectable vaccine made locally from inactivated whole cells. This campaign was highly effective in reducing the incidence of typhoid fever in Thailand and did not compromise the general plan to improve sanitation [3] . The Thai typhoid vaccination program had a nationwide impact on typhoid rates. The CDC recommendations, which did not include vaccination, might have been effective for Dushanbe but would be unlikely to affect the rest of the country, where high rates of typhoid were also reported.
In contrast to Thailand in the 1980s, Tajikistan was experiencing political instability and civil unrest during the epidemic, which may have limited the vaccination option. In contrast, mass typhoid vaccination campaigns can be quite practical if they are targeted at school-age children and if the logistics of immunization are school based. In most large typhoid outbreaks in developing countries, as well as in most endemic situations, approximately two-thirds of reported cases occur in school-age children, 5-19 years of age [4] . A large school-based intervention with live oral typhoid vaccine Ty21a in Santiago, Chile, in the early 1980s involving ∼200,000 children showed that this was practical even though multiple doses were administered [5] . Moreover, there was evidence that largescale use of Ty21a in 4 field trials in Santiago resulted in a herd immunity effect that interfered with transmission and lowered the incidence in segments of the populations that did not receive vaccine [6] . Typhoid immunization has been effectively introduced among school-age children living in high-risk areas of neighboring Uzbekistan. The current opinion of the WHO Scientific Advisory Group of Experts is that immunization of school-age children should be undertaken in geographical areas where typhoid fever is a recognized public health problem and antibiotic-resistant Salmonella typhi strains are particularly prevalent. Immunization can be complementary to sanitation in reducing typhoid rates [7] .
Two available typhoid vaccines, oral Ty21a and parenteral purified Vi polysaccharide, are well tolerated, moderately protective, and practical to use [4] . Moreover, in recent years, their cost has markedly diminished. An economic analysis of the use of typhoid vaccines in endemic situations revealed that 2 parameters in particular-the incidence of the disease and the duration of protection-had a favorable impact on the cost effectiveness of vaccination [8] . Whether the vaccine is 70% or 90% effective does not appreciably alter the equation. From this perspective, it was notable that in 2 separate field trials in Chile, Ty21a conferred impressively long-term protection. In the Area Occidente trial, 3 doses of enteric-coated capsules conferred 62% protection for 7 years, and in a separate study in Areas Sur Oriente and Norte, 3 doses of the liquid formulation conferred 78% protection over 5 years of follow-up [9] .
Vi vaccine also provided good protection when administered in countries with a high incidence of typhoid fever [10] . In a field trial in South Africa, a single dose of Vi polysaccharide had a vaccine efficacy of 55% for at least 3 years [11] . The typhoid vaccines currently available should be considered for a larger role in public health control programs [12] . 
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